Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.31 |
| ▸ | SORD | Q00796 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068014 | 0.89 | METAP2 (0.39) | PIM1PIM3PIM2PDE10ASMPD3 | |
| SCHEMBL2069492 | 0.89 | METAP2 (0.39) | PIM1PIM3PIM2PDE10ASMPD3 | |
| SCHEMBL2068725 | 0.89 | METAP2 (0.39) | PIM1PIM3PIM2PDE10ASMPD3 | |
| SCHEMBL2068403 | 0.77 | KDM4E (0.40) | PDE10ASMPD3 | |
| SCHEMBL2067363 | 0.77 | HTR3E (0.37) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL2794429 | 0.74 | PDE10A (0.33) | PDE10ASMPD3SORD | |
| SCHEMBL2068582 | 0.73 | MAP4K4 (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL22529934 | 0.72 | HTR3E (0.47) | — | |
| SCHEMBL1819991 | 0.72 | KMT2A (0.46) | SMPD3 | |
| SCHEMBL22153186 | 0.69 | PDE10A (0.35) | PIM1PIM3PIM2PDE10ATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102803259-A | 1H-Imidazo[4, 5-c]quinolinone compounds, useful for the treatment of proliferative diseases | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | PIM1 368/4885PIM3 432/4885PIM2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.